Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline

On August 18, 2021 Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, reported it had secured a $40 million Series B funding round denominated in both U.S. dollars and Chinese yuan (Press release, Ranok Therapeutics, AUG 18, 2021, View Source [SID1234586729]). The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors. To date, Ranok has raised the equivalent of over $50 million in funding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP (Chaperone-mediated Protein Degradation), that leverages Ranok’s founders’ expertise in protein homeostasis to take advantage of the cellular chaperome network, potentially improving drug safety and efficacy due to selective targeting of disease tissues.

"We are delighted by the enthusiastic response from investors to this financing, which is a strong endorsement of Ranok’s strategic vision and research programs," said Weiwen Ying, Ph.D., Founder and Chief Executive Officer of Ranok Therapeutics. "These funds will enable us to advance our first cancer therapy into clinical trials in the near future and continue to progress our pipeline of novel CHAMP targeted protein degraders. We believe our approach may provide important benefits both in safety and in efficacy for areas of significant unmet need. We welcome our new investors and greatly appreciate the continued support of our existing investors."

"We are very optimistic about the direction and opportunity of the emerging field of TPD and its application to traditionally undruggable disease targets. Ranok’s founders, who bring decades of experience in protein degradation, have developed a unique technology platform that is highly differentiated from competing degrader approaches. We are delighted to work with innovative companies such as Ranok and look forward to helping quickly and efficiently bring their novel medicines to patients," said Zhihua Yu, Chairman of Lapam Capital.

"TPD is an exciting new paradigm in drug development, and Ranok’s CHAMP technology has unique advantages in comparison to other protein degrader approaches, such as PROTAC," said Hong Wen, Ph.D., Partner at Shanghai Healthcare Capital. "We share Ranok’s vision to become a leading protein degradation therapy company with a global impact by creating breakthrough medicines for patients suffering from cancer and other diseases."

The Series B financing proceeds will support continued development of Ranok’s most advanced cancer program, which is expected to be announced by the end of 2021, as well as expansion of its preclinical pipeline of novel therapies based on the proprietary CHAMP technology platform.